Jiangsu Hengrui Pharmaceuticals(600276.SH): SHR-1139 Injection Receives Approval for Clinical Trials of Drugs

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the injection SHR-1139. The clinical trials will be conducted soon. SHR-1139 injection is a biopharmaceutical developed independently by the company, expected to synergistically enhance the treatment of ulcerative colitis by inhibiting inflammatory reactions and maintaining the epithelial barrier. It has been found that there are currently no similar drugs approved for market in China or overseas. As of now, the total investment in the SHR-1139 injection project has reached approximately 71.28 million yuan.